LexaGene is a biotechnology company developing automated and sensitive instrumentation for rapid pathogen detection.
Our breakthrough technology will transform how pathogens are detected and deliver results in about an hour.
15 August 2017 – LexaGene names life sciences veteran Manohar Furtado to the board of directors. New director brings extensive human health and safety leadership experience to the company.
Innovation in the Making
Imagine a new way of testing on site for multiple pathogens that uses customized genetic screening, doesn’t requite a skilled technician,
and returns results in just one hour. See what’s new with LexaGene and how we are changing the future of pathogen detection.
We are commercializing the first ‘open-access’ instrument for pathogen detection, allowing users an on-site instrument to target any gene sequence of interest, and return results in about an hour.
Introducing the LX6
At a recent conference, LexaGene unveiled our LX6 alpha prototype to get early feedback from the food safety market.
LexaGene on The Street
Investment news outlet, The Street, speaks to LexaGene about its revolutionary pathogen detection system, and the company’s plans after the end of November 2017 when phase IV is completed.